Nam Hee Kim1, Jae Wan Lim2, Sunyong Kim1, Ji Yeon Lim1, Wonsool Kim1, Jung Ho Park2, Dong Il Park2, Chong Il Sohn2, Yoon Suk Jung3. 1. Preventive Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea. 2. Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea. 3. Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: ys810.jung@samsung.com.
Abstract
BACKGROUND: We evaluated the risk of advanced colorectal neoplasia (ACRN) and colorectal cancer (CRC) according to time to colonoscopy after positive fecal immunochemical test (FIT), fecal hemoglobin concentration, and combination of both. METHODS: We analyzed the records of 2362 patients aged ≥50 years who underwent colonoscopy because of a positive FIT result through the National Cancer Screening Program of Korea. RESULTS: ACRN risk increased with increasing time to colonoscopy after a positive FIT (17.2%, 18.6%, 19.1%, 21.4%, and 27.2% in <30, 30-59, 60-149, 150-179, and ≥180 days; P = 0.034), and ACRN and CRC risk increased with increasing fecal hemoglobin concentration (ACRN, 13.2%, 16.9%, 18.5%, 23.2%, and 26.6%; CRC, 1.3%, 1.7%, 4.7%, 5.7%, and 12.8% with 100-200, 200-300, 300-500, 500-1000, and ≥1000 ng Hb/mL; both P < 0.001). Even after adjusting for confounders, follow-up after 180 days tended to be associated with a higher ACRN risk (adjusted odds ratio, 1.73; 95% confidence interval [CI], 0.91-3.27), compared with follow-up colonoscopy at <30 days, and fecal hemoglobin 500-1000, and ≥1000 ng Hb/mL were associated with a significantly higher ACRN and CRC risk, compared with 100-200 ng Hb/mL. Moreover, the group with ≥180 days and ≥1000 ng Hb/mL had a much higher CRC risk compared with the group with <180 days and <1000 ng Hb/mL (12.45-fold; 95% CI, 3.73-41.57). CONCLUSIONS: Patients with positive FIT results, especially those with higher fecal hemoglobin levels, should undergo timely follow-up colonoscopy.
BACKGROUND: We evaluated the risk of advanced colorectal neoplasia (ACRN) and colorectal cancer (CRC) according to time to colonoscopy after positive fecal immunochemical test (FIT), fecal hemoglobin concentration, and combination of both. METHODS: We analyzed the records of 2362 patients aged ≥50 years who underwent colonoscopy because of a positive FIT result through the National Cancer Screening Program of Korea. RESULTS: ACRN risk increased with increasing time to colonoscopy after a positive FIT (17.2%, 18.6%, 19.1%, 21.4%, and 27.2% in <30, 30-59, 60-149, 150-179, and ≥180 days; P = 0.034), and ACRN and CRC risk increased with increasing fecal hemoglobin concentration (ACRN, 13.2%, 16.9%, 18.5%, 23.2%, and 26.6%; CRC, 1.3%, 1.7%, 4.7%, 5.7%, and 12.8% with 100-200, 200-300, 300-500, 500-1000, and ≥1000 ng Hb/mL; both P < 0.001). Even after adjusting for confounders, follow-up after 180 days tended to be associated with a higher ACRN risk (adjusted odds ratio, 1.73; 95% confidence interval [CI], 0.91-3.27), compared with follow-up colonoscopy at <30 days, and fecal hemoglobin 500-1000, and ≥1000 ng Hb/mL were associated with a significantly higher ACRN and CRC risk, compared with 100-200 ng Hb/mL. Moreover, the group with ≥180 days and ≥1000 ng Hb/mL had a much higher CRC risk compared with the group with <180 days and <1000 ng Hb/mL (12.45-fold; 95% CI, 3.73-41.57). CONCLUSIONS:Patients with positive FIT results, especially those with higher fecal hemoglobin levels, should undergo timely follow-up colonoscopy.
Authors: Chi Thi-Du Tran; Mai Vu-Tuyet Nguyen; Mo Thi Tran; Thuy Thi-Van Tuong; Quang Hong Tran; Linh Cu Le; Huong Thi-Thu Pham; Nam Chi Bui; Hien Huy Vu; Tu Thi-Cam Nguyen; Phuong Que Ta; Hien Thi-Thu Ha; Dung Tuan Trinh; Hanh Thi-My Bui; Dien Quang Trinh; Khanh Van Nguyen; Song Huu Le; Khien Van Vu; Thuan Van Tran; Huong Thi-Thanh Tran; Martha J Shrubsole; Fei Ye; Qiuyin Cai; Wei Zheng; Paolo Boffetta; Xiao-Ou Shu; Hung N Luu Journal: Jpn J Clin Oncol Date: 2022-07-08 Impact factor: 2.925
Authors: Yazmin San Miguel; Joshua Demb; Maria Elena Martinez; Samir Gupta; Folasade P May Journal: Gastroenterology Date: 2021-02-02 Impact factor: 22.682
Authors: Farah Ballout; Reem Daouk; Joseph Azar; Michael Timonian; Tarek Araji; Hisham F Bahmad; Wassim Abou-Kheir Journal: SN Compr Clin Med Date: 2020-09-30
Authors: Luigi Ricciardiello; Clarissa Ferrari; Michela Cameletti; Federica Gaianill; Francesco Buttitta; Franco Bazzoli; Gian Luigi de'Angelis; Alberto Malesci; Luigi Laghi Journal: Clin Gastroenterol Hepatol Date: 2020-09-06 Impact factor: 11.382